Home Featured Page 177

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health...

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Opening the Mushroom Pharmacopeia: The Case of Norbaeocystin

PT343 – Soren Shade – Kratom and Anti-Prohibition: Lessons Learned and...

COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord...

Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results

atai Life Sciences to Announce Second Quarter 2022 Financial Results and...

BREAKING: Morgan Stanley Publishes Optimistic Report on Psychedelics

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study...

FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health...

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Opening the Mushroom Pharmacopeia: The Case of Norbaeocystin

PT343 – Soren Shade – Kratom and Anti-Prohibition: Lessons Learned and...

COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord...

Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results

atai Life Sciences to Announce Second Quarter 2022 Financial Results and...

BREAKING: Morgan Stanley Publishes Optimistic Report on Psychedelics

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study...

FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY